Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

Mateos, María-Victoria, Hernández, Miguel-Teodoro, Giraldo, Pilar, de la Rubia, Javier, de Arriba, Felipe, Corral, Lucía López, Rosiñol, Laura, Paiva, Bruno, Palomera, Luis, Bargay, Joan, Oriol, Albert, Prosper, Felipe, López, Javier, Arguiñano, José-María, Quintana, Nuria, García, José-Luis, Bladé, Joan, Lahuerta, Juan-José, Miguel, Jesús-F San · 2016 · The Lancet Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30124-3

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 18

  1. 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x · DOI · Paper page
  2. Mateos, 2015, Smoldering multiple myeloma, Hematol Oncol, 33, 33, 10.1002/hon.2213 · DOI
  3. Perez-Persona, 2007, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, Blood, 110, 2586, 10.1182/blood-2007-05-088443 · DOI · Paper page
  4. Rollig, 2015, Multiple myeloma, Lancet, 385, 2197, 10.1016/S0140-6736(14)60493-1 · DOI · Paper page
  5. Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
  6. Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
  7. Dimopoulos, 2012, A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide, Blood, 119, 2764, 10.1182/blood-2011-08-373514 · DOI
  8. Riccardi, 2000, Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma, Br J Cancer, 82, 1254, 10.1054/bjoc.1999.1087 · DOI
  9. Martin, 2002, Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect, Br J Haematol, 118, 239, 10.1046/j.1365-2141.2002.03549.x · DOI
  10. Musto, 2008, A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma, Cancer, 113, 1588, 10.1002/cncr.23783 · DOI · Paper page
  11. D'Arena, 2011, Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study, Leuk Lymphoma, 52, 771, 10.3109/10428194.2011.553000 · DOI
  12. Lust, 2009, Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component, Mayo Clin Proc, 84, 114, 10.4065/84.2.114 · DOI · Paper page
  13. Rajkumar, 2003, Thalidomide as initial therapy for early-stage myeloma, Leukemia, 17, 775, 10.1038/sj.leu.2402866 · DOI · Paper page
  14. Weber, 2003, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma, J Clin Oncol, 21, 16, 10.1200/JCO.2003.03.139 · DOI · Paper page
  15. Barlogie, 2008, Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease, Blood, 112, 3122, 10.1182/blood-2008-06-164228 · DOI
  16. Witzig, 2013, A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma, Leukemia, 27, 220, 10.1038/leu.2012.236 · DOI
  17. Rajkumar, 2015, Smoldering multiple myeloma, Blood, 125, 3069, 10.1182/blood-2014-09-568899 · DOI · Paper page
  18. Korde, 2015, Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma, JAMA Oncol, 1, 746, 10.1001/jamaoncol.2015.2010 · DOI · Paper page

Cited by

See all 193

Metadata

Authors
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., Oriol, A., Prosper, F., López, J., Arguiñano, J.-M., Quintana, N., García, J.-L., Bladé, J., Lahuerta, J.-J., & Miguel, J.-F. S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2016-08
Volume
17
Issue
8
Pages
1127-1136
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2469453488
Cited by
193
References
9
FWCI
11.85
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30124-3
The paper
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., Oriol, A., Prosper, F., López, J., Arguiñano, J.-M., Quintana, N., García, J.-L., Bladé, J., Lahuerta, J.-J., & Miguel, J.-F. S. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30124-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.